Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 3/20 | 0.49 |
| ▸ | RXRB | P28702 | 3/20 | 0.49 |
| ▸ | RXRG | P48443 | 3/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8931020 | 0.90 | KDM4E (0.48) | KDM4EALDH1A1HSD17B10HPGDMEN1 | |
| SCHEMBL930765 | 0.88 | TLR8 (0.43) | RXRARXRBRXRGRECQLKDM4E | |
| SCHEMBL12908632 | 0.82 | TLR8 (0.42) | ALDH1A1HSD17B10NPSR1HPGDMEN1 | |
| SCHEMBL8931412 | 0.81 | HSP90AA1 (0.40) | KDM4EALDH1A1HSD17B10NPSR1HPGD | |
| SCHEMBL931433 | 0.81 | TLR8 (0.52) | RECQLKDM4EALDH1A1HSD17B10NPSR1 | |
| SCHEMBL4944734 | 0.80 | TSHR (0.46) | POLBPRNPRXFP1HSP90AA1HSP90AB1 | |
| SCHEMBL930634 | 0.79 | TLR8 (0.39) | KDM4EALDH1A1HSD17B10HPGDMEN1 | |
| SCHEMBL931818 | 0.77 | HSP90AA1 (0.43) | ALDH1A1HPGDMEN1KMT2AHSP90AA1 | |
| SCHEMBL930617 | 0.75 | HSP90AA1 (0.42) | ALDH1A1HPGDMEN1KMT2ANPC1 | |
| SCHEMBL14184187 | 0.75 | HSP90AA1 (0.42) | KDM4EALDH1A1HSD17B10HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2298748-B1 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-2295416-B1 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP (US) | 2016-01-27 | — | — | EP | disclosed |
| US-9090569-B2 | Triazone compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20150150851-A1 | FORMULATION AND DOSING OF HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-04 | — | — | US | disclosed |
| US-20140363830-A1 | COMPOUNDS THAT MODULATE HSP90 ACTIVITY AND METHODS FOR IDENTIFYING SAME | SYNTA PHARMACEUTICALS CORP. (US) | 2014-12-11 | — | — | US | disclosed |
| US-20130172333-A1 | FORMULATION AND DOSING OF HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2013-07-04 | — | — | US | disclosed |
| US-8362055-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| EP-1817295-B1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011146801-A1 | FORMULATION AND DOSING OF HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2011-11-24 | — | — | WO | disclosed |
| US-20110105749-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2011-05-05 | — | — | US | disclosed |
| EP-2298748-A2 | Triazole compounds that modulate HSP90 activity | Synta Pharmaceuticals Corp. (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2295416-A2 | Triazole compounds that modulate HSP90 activity | Synta Pharmaceuticals Corp. (US) | 2011-03-16 | — | — | EP | disclosed |
| US-20110009397-A1 | TRIAZONE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2011-01-13 | — | — | US | disclosed |
| US-7825148-B2 | heat shock protein 90 inhibitors such as 3-(2-Hydroxyphenyl)-4-(naphthalen-1-yl)-5-mercapto-triazole, used for for preventing or treating hyperproliferative disorders, such as cancer | SYNTA PHARMACEUTICALS CORP. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20080125587-A1 | Synthesis of triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. | 2008-05-29 | — | — | US | disclosed |
| US-20080027047-A1 | Compounds that modulate HSP90 activity and methods for identifying same | SYNTA PHARMACEUTICALS CORP | 2008-01-31 | — | — | US | disclosed |
| US-20060167070-A1 | heat shock protein 90 inhibitors such as 3-(2-Hydroxyphenyl)-4-(naphthalen-1-yl)-5-mercapto-triazole, used for for preventing or treating hyperproliferative disorders, such as cancer | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125587-A1 | Synthesis of triazole compounds that modulate HSP90 activity | HSP90AB1, HSP90AA1, HSP90AB2P | RXRA 4232/4885RXRB 4247/4885RXRG 4548/4885 |
| US-20130172333-A1 | FORMULATION AND DOSING OF HSP90 INHIBITORY COMPOUNDS | HSP90AB1, HSP90AA1, HSP90AB2P | RXRA 2800/4885RXRB 2760/4885RXRG 2655/4885 |
| US-20110009397-A1 | TRIAZONE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90AB2P, HSP90AA1 | RXRA 3695/4885RXRB 3584/4885RXRG 3648/4885 |
| US-20150150851-A1 | FORMULATION AND DOSING OF HSP90 INHIBITORY COMPOUNDS | HSP90AB1, HSP90AA1, HSP90AB2P | RXRA 2800/4885RXRB 2760/4885RXRG 2655/4885 |
| US-20080027047-A1 | Compounds that modulate HSP90 activity and methods for identifying same | HSP90AB1, HSP90B1, CDC37 | RXRA 3901/4885RXRB 3952/4885RXRG 3598/4885 |
| US-20110105749-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | RXRA 3480/4885RXRB 3410/4885RXRG 3376/4885 |
| US-20060167070-A1 | heat shock protein 90 inhibitors such as 3-(2-Hydroxyphenyl)-4-(naphthalen-1-yl)-5-mercapto-triazole, used for for preventing or treating hyperproliferative disorders, such as cancer | HSP90AB1, HSP90AB2P, HSP90AA1 | RXRA 3471/4885RXRB 3514/4885RXRG 3468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.